|Bid||0.00 x 0|
|Ask||0.00 x 0|
|Day's Range||113.59 - 116.73|
|52 Week Range||63.12 - 125.86|
|PE Ratio (TTM)||34.46|
|Earnings Date||Apr 25, 2018 - Apr 30, 2018|
|Forward Dividend & Yield||3.84 (3.34%)|
|1y Target Est||125.90|
AstraZeneca, Bristol and Vertex are the likeliest targets of widespread mergers and acquisitions across the biopharma group.
Merck gains priority review for Keytruda in advanced cervical cancer, AbbVie's elagolix meets primary endpoint in second phase III study.
The only "problem" mentioned by Vertex CEO Jeff Leiden? It's accumulating cash rapidly.
Zacks Market Edge Highlights: Scotts Miracle-Gro, GW Pharmaceuticals, Innovative Industrial Properties and AbbVie
Visa, AbbVie and Tencent are in different fields but have very similar stock charts, reflecting the action of the major averages.
AbbVie (ABBV) and partner Neurocrine Biosciences announce that the second of the two pivotal phase III studies evaluating elagolix, met the primary endpoint for treating women with uterine fibroids.
− Second of two pivotal Phase 3 studies (ELARIS UF-II) met primary efficacy endpoint and all ranked secondary endpoints − Results were consistent with the first Phase 3 study (ELARIS UF-I) and demonstrated ...
A pharmaceutical stock and a consumer goods giant make up two of these three attractive investments for those approaching retirement.
More prisoners with hepatitis C are becoming eligible for treatment with effective but costly drugs like Harvoni and Sovaldi from Gilead Sciences Inc., as a result of lawsuits filed by inmates in Massachusetts ...